Loading organizations...
§ Venture Capital · Seongnam, Kyonggi-do, South Korea
Holding company funding therapeutic medicine development via subsidiaries, focused on neurodegenerative and metabolic diseases.
D&D Pharmatech has raised $188.1M across 2 funding rounds.
Key people at D&D Pharmatech.
D&D Pharmatech was founded in 2014 by Kang Choon Lee (Co-founder) and Seulki Lee (Founder and CEO) and Viktor Roschke (Co-founder).
D&D Pharmatech has raised $188.1M in total across 2 funding rounds.
Based in Pangyo, South Korea, D&D Pharmatech is a clinical-stage holding company that funds and develops therapeutic medicines for neurodegenerative, metabolic, and fibrotic diseases through disease-specific subsidiary companies. The biotechnology firm advances a diverse pipeline of treatments, including oral GLP-1 medicines licensed to Metsera, alongside active clinical trials for Parkinson’s disease, Alzheimer’s disease, and obesity. Operating with fewer than 25 employees and generating under $5 million in annual revenue, the enterprise has secured $188.1 million in total venture funding, which includes a $51 million Series C round. Following preliminary approval for a Kosdaq initial public offering in late 2023, the company continues to be backed by prominent investors such as Peter Thiel's Octave Life Sciences, Praxis Capital Partners, and Smilegate Investment. D&D Pharmatech was founded in 2014 by Seulki Lee and Kang Choon Lee.
D&D Pharmatech was founded in 2014 by Kang Choon Lee (Co-founder) and Seulki Lee (Founder and CEO) and Viktor Roschke (Co-founder).
D&D Pharmatech has raised $188.1M in total across 2 funding rounds.
D&D Pharmatech's investors include Minsang La, DS Asset Management, Korea Investment & Securities, Kudos Ventures, Octave Life Sciences, Smilegate Investment, InterVest, LB Investment, Magna Investment.
D&D Pharmatech has raised $188.1M across 2 funding rounds. Most recently, it raised $51.0M Series C in October 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 2, 2021 | Valted Seq | $10.5M Seed | Dongkoo Bio&pharma | OV Principal Investments |
| Jul 18, 2018 | Neuraly | $36.0M Series A | D&D Pharmatech | Dongkoo Bio&pharma, Geon Investment, Junghee LIM, LB Investment, Keele Park, Phillip Jung, Octave Life Sciences, John KU |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 19, 2021 | $51M Series C | Minsang LA | DS Asset Management, Korea Investment & Securities, Kudos Ventures | Announced |
| Aug 14, 2019 | $137.1M Series B | Octave Life Sciences, Smilegate Investment | Intervest, LB Investment, Magna Investment | Announced |
Key people at D&D Pharmatech.
